SELB 5-Month Data Update

SEL-212 data looks good thru 5 months, and therapy appears more likely approvable with future phase 3 trial, but data not exceptional because of early drop-outs. Negative market reaction to SELB data (currently at -30%) seems to be an incorrect reaction. However, negative reaction to competitor HZNP too (-10%), seems counterintuitive. Phase 3 can likely reduce early drop-outs by relaxing stopping rules, but this might increase infusion reactions. Long-term now more likely we will have 2 player market for gout patients with KRYSTEXXA + general immunomodulators vs. SEL-212. That should be good news for gout patients.


*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon